Winning Stock Forecast: Acadia, Protalix Bring Big Returns In The BioTech Space
ACAD Winning Stock Forecast
By Pöllö -commons.wikimedia.org
This week ACAD saw a 52.38% jump, being the 7 day forecast’s biggest earner, as the I Know First algorithm predicted. Before this week, ACAD’s shares have been under pressure from what turned out to be an inaccurate report from CNN. Acadia Pharmaceuticals is again bringing in impressive returns. The drug under fire was Nuplazid. The FDA only recently discarded these allegations to be untrue. Nuplazid made up $57.1 million in sales Q2 for ACAD, an 18% increase from the first quarter. Sales of the drug are increasing 87% year over year. The